RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 98 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $238,306 | +39.5% | 10,395 | +0.3% | 0.00% | – |
| Q2 2023 | $170,854 | +10.2% | 10,361 | -23.1% | 0.00% | – |
| Q1 2022 | $155,000 | -7.7% | 13,465 | -19.4% | 0.00% | – |
| Q4 2021 | $168,000 | -21.5% | 16,707 | +2.0% | 0.00% | -100.0% |
| Q3 2021 | $214,000 | -46.5% | 16,375 | -19.9% | 0.00% | 0.0% |
| Q2 2021 | $400,000 | +10.5% | 20,450 | +20.3% | 0.00% | 0.0% |
| Q1 2021 | $362,000 | -14.6% | 16,996 | +19.1% | 0.00% | -50.0% |
| Q4 2020 | $424,000 | +74.5% | 14,269 | +27.1% | 0.00% | +100.0% |
| Q3 2020 | $243,000 | -6.2% | 11,229 | -3.3% | 0.00% | 0.0% |
| Q2 2020 | $259,000 | -16.2% | 11,612 | -13.8% | 0.00% | 0.0% |
| Q4 2019 | $309,000 | +19.8% | 13,472 | +12.7% | 0.00% | 0.0% |
| Q3 2019 | $258,000 | +0.4% | 11,958 | +2.5% | 0.00% | -50.0% |
| Q2 2019 | $257,000 | -29.8% | 11,661 | -12.6% | 0.00% | 0.0% |
| Q1 2019 | $366,000 | +2.5% | 13,343 | +0.6% | 0.00% | 0.0% |
| Q4 2018 | $357,000 | – | 13,266 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |